Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder

Amital, Daniela; Fostick, Leah; Silberman, A.; Calati, Raffaella; Spindelegger, Christoph; Serretti, Alessandro; Juven‐Wetzler, Alzbeta; Souery, Daniel; Mendlewicz, Julien; Montgomery, Stuart; Kasper, Siegfried; Zohar, Joseph

doi:10.1016/j.euroneuro.2012.09.002

Cited by 33 publications

(21 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients at age<60 years had greater response to repetitive transcranial magnetic stimulation compared to older patients (Pallanti et al 2012). On the other hand, our results are in line with data from Amital et al (2012), who found no difference between TRD and non-TRD patients in the prevalence of comorbid somatic disorders, including diabetes, hypertension and ischemic heart disease. Although the prevalence of MetS increases with age, it is possible that factors other than MetS, influence poorer response to antidepressants in older age.…”

Section: Discussionsupporting

confidence: 82%

The lack of association between components of metabolic syndrome and treatment resistance in depression

et al. 2013

View full text Add to dashboard Cite

(2013) The lack of association between components of metabolic syndrome and treatment resistance in depression. npivac@irb.hr Psychopharmacology, 230 (1). Conflicts of Interest:Authors declare no conflict of interest. All authors state that they have full control of all primary data and that they agree to allow the journal to review this data. Acknowledgments:This study was supported by the Croatian Ministry of Science, Education and Sport, grants numbers 098-0982522-2455; 098-0982522-2457; 109-1083509-3513; 108-1083509-3511.

show abstract

Section: Discussionsupporting

confidence: 82%

The lack of association between components of metabolic syndrome and treatment resistance in depression

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The analyses revealed a significant association between high occupational level and poorer treatment response in comparison with medium and low occupational levels (Mandelli et al, 2016). With respect to somatic comorbidities in MDD, no significant differences were found between responders and treatment-resistant patients in a sample of 702 patients with MDD (Amital et al, 2013). In terms of family history, Serretti et al (2014) reported no statistically significant differences between patients with and without a family history of MDD when analyzing overall depressive symptoms.…”

Section: B Features Contributing To Treatment Resistancementioning

confidence: 84%

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets

et al. 2018

Self Cite

View full text Add to dashboard Cite

Major depressive disorder is one of the most prevalent and life-threatening forms of mental illnesses and a major cause of morbidity worldwide. Currently available antidepressants are effective for most patients, although around 30% are considered treatment resistant (TRD), a condition that is associated with a significant impairment of cognitive function and poor quality of life. In this respect, the identification of the molecular mechanisms contributing to TRD represents an essential step for the design of novel and more efficacious drugs able to modify the clinical course of this disorder and increase remission rates in clinical practice. New insights into the neurobiology of TRD have shed light on the role of a number of different mechanisms, including the glutamatergic system, immune/inflammatory systems, neurotrophin function, and epigenetics. Advances in drug discovery processes in TRD have also influenced the classification of antidepressant drugs and novel classifications are available, such as the neuroscience-based nomenclature that can incorporate such advances in drug development for TRD. This review aims to provide an up-to-date description of key mechanisms in TRD and describe current therapeutic strategies for TRD before examining novel approaches that may ultimately address important neurobiological mechanisms not targeted by currently available antidepressants. All in all, we suggest that drug targeting different neurobiological systems should be able to restore normal function but must also promote resilience to reduce the long-term vulnerability to recurrent depressive episodes.

show abstract

“…The initial electronic database search resulted in 145 valid hits. From candidate publications following exclusions, our search generated 17 publications [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] fulfilling the inclusion criteria (see Fig. 1 for search results, including reasons for exclusion).…”

Section: Search Results and Included Participantsmentioning

confidence: 99%

“…Details on the included studies are presented in Table 1. Of the 16 publications included in the pooled analysis, two [32,35] were conducted among inpatients (n = 1,794), one [36] was conducted in an outpatient setting (n = 72), two [40,42] were conducted in mixed samples (n = 5,295) and eleven [31,33,34,36,37,39,41,[43][44][45]47] included community patients (n = 151,673). Only three studies [32,34,38] (n = 933) reported the prevalence of participants that smoked, and 47.8% of patients with MDD in these studies were smokers.…”

Section: Search Results and Included Participantsmentioning

confidence: 99%

Type 2 Diabetes in Patients With Major Depressive Disorder: A Meta-Analysis of Prevalence Estimates and Predictors

et al. 2015

View full text Add to dashboard Cite

show abstract

Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder

Cited by 33 publications

References 49 publications

The lack of association between components of metabolic syndrome and treatment resistance in depression

The lack of association between components of metabolic syndrome and treatment resistance in depression

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets

Type 2 Diabetes in Patients With Major Depressive Disorder: A Meta-Analysis of Prevalence Estimates and Predictors

Contact Info

Product

Resources

About